Drug Trial Radar · NCT07681713
Long-Term Efficacy Study of Vatiquinone for the Treatment of Friedreich's Ataxia (FA)
Last checked: Nov 20, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Aug 15, 2026
Primary completion
Mar 15, 2029
Study completion Mar 15, 2029
Sponsor
- Lead sponsor
- PTC TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jul 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 7 years, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to confirm the treatment effects of vatiquinone on the key measures of FA disease progression.
Conditions
- Friedreich's Ataxia
Interventions
VatiquinoneDrug
Vatiquinone will be administered per dose and schedule specified in the arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Total Modified Friedreich's Ataxia Rating Scale (mFARS) Score at Month 24Time frame: Baseline, Month 24
Locations
9 sites in 6 countries. Site status is shown where the registry gives one.
University of California Los Angeles
Los Angeles, California
University of South Florida
Tampa, Florida
University of Iowa
Iowa City, Iowa
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Hôpital Érasme (Hôpital Universitaire de Bruxelles)
Brussels, Belgium
University of Campinas
Campinas, São Paulo, Brazil
Centre Hospitalier de l'Universite de Montreal CHUM
Montreal, Quebec, Canada
Institut du Cerveau et de la Moelle Epinière
Paris, France
Hospital Sant Joan de Deu
Barcelona, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.